$Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension$

Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension

Abstract Sacubitril/valsartan, simultaneously inhibits neprilysin and angiotensin II receptor, showed an effect in reducing blood pressure (BP). The authors aimed to study whether it can be used as an antihypertensive agent in patients with refractory hypertension who have already been treated. A to...

Full description

Bibliographic Details
Main Authors:	Wanjing Li, Minghui Gong, Qin Yu, Rihui Liu, Kaiming Chen, Wei Lv, Fumei Yao, Zhaolong Xu, Yi Xu, Wei Song, Yinong Jiang
Format:	Article
Language:	English
Published:	Wiley 2022-04-01
Series:	The Journal of Clinical Hypertension
Subjects:	ambulatory blood pressure monitoring angiotensin receptor neprilysin inhibitor Asia refractory hypertension sacubitril/valsartan
Online Access:	https://doi.org/10.1111/jch.14454

Similar Items

Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis
by: Wipharak Rattanavipanon, et al.
Published: (2021-07-01)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
by: Jahanzeb Malik, et al.
Published: (2021-09-01)

Safety and effectiveness of angiotensin receptor-neprilysin inhibitors in Indian patients with heart failure with preserved ejection fraction – “ARNI-PRESERVED” study
by: Pankaj Jariwala, et al.
Published: (2021-01-01)

Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP‐HF
by: Brittany Chapman, et al.
Published: (2022-06-01)

Initiation, treatment response evaluation, and safety monitoring of angiotensin receptor/neprilysin inhibitors (Sacubitril/Valsartan) in the management of heart failure in India: An expert group recommendations
by: Uday M Jadhav, et al.
Published: (2023-01-01)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
by: Kawa Dizaye, et al.
Published: (2019-05-01)

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis
by: Pankaj Jariwala, et al.
Published: (2021-03-01)

Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
by: M. O.E. Irhuma, et al.
Published: (2016-11-01)

Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Neprilysin Inhibitors in Patients With Heart Failure
by: Amrita Mukhopadhyay, et al.
Published: (2022-12-01)

Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial
by: Julie Hempel Larsen, et al.
Published: (2023-02-01)

The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Sharath Kommu, et al.
Published: (2024-03-01)

Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor
by: Teng Y, et al.
Published: (2023-08-01)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
by: Nathalie Esser, et al.
Published: (2022-06-01)

Characteristics and Treatments of Patients Enrolled in the CHAMP‐HF Registry Compared With Patients Enrolled in the PARADIGM‐HF Trial
by: Adam D. DeVore, et al.
Published: (2018-06-01)

INNOVATIVE STRATEGY IN THERAPY OF CARDIAC INSUFFICIENCY
by: N. A. Jaiani
Published: (2017-11-01)

Effect of Angiotensin–Neprilysin Versus Renin–Angiotensin System Inhibition on Renal Outcomes: A Systematic Review and Meta-Analysis
by: Ying Xu, et al.
Published: (2021-11-01)

Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study
by: Dong-Yi Chen, et al.
Published: (2021-11-01)

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
by: Ying Ding, et al.
Published: (2023-12-01)

Combined drug sacubitril/valsartan -a new era of treatment of chronic heart failure
by: V. S. Nikiforov
Published: (2020-10-01)

Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials
by: Yake Lou, et al.
Published: (2022-08-01)

Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy
by: Wei-Chieh Lee, et al.
Published: (2023-04-01)

Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
by: Tomoko Kato, et al.
Published: (2023-09-01)

Moving Beyond Self‐Reported Race in Our Understanding of Cardiovascular Medicine
by: Nancy Luo
Published: (2022-06-01)

Is there a role for renin–angiotensin–aldosterone system and neprilysin inhibition in the failing systemic right ventricle?
by: Diamantis Kosmidis, et al.
Published: (2021-05-01)

Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity
by: Aleksandra M. Sobiborowicz-Sadowska, et al.
Published: (2023-01-01)

Clinical Outcomes in Patients with Ischemic versus Non-Ischemic Cardiomyopathy after Angiotensin-Neprilysin Inhibition Therapy
by: Mohammad Abumayyaleh, et al.
Published: (2021-10-01)

Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure
by: Yuxi Sun, et al.
Published: (2022-02-01)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
by: Mi‐Gil Moon, et al.
Published: (2021-06-01)

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
by: Yandrapalli S, et al.
Published: (2017-10-01)

Angiotensin Receptor‐Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension
by: Danial Sharifi Kia, et al.
Published: (2020-07-01)

Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
by: Katie L. Peppin, et al.
Published: (2020-01-01)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
by: Nor Hidayah Mustafa, et al.
Published: (2022-08-01)

Heart failure signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril/valsartan in primary care and cardiologist settings in Germany
by: Rolf Wachter, et al.
Published: (2020-10-01)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
by: A.S. Ryazanov, et al.
Published: (2023-04-01)

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
by: Hong-Mi Choi, et al.
Published: (2020-05-01)

Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure – A prospective observational study
by: Tahir Saleem Bhat, et al.
Published: (2022-05-01)

Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis
by: Pei Yang, et al.
Published: (2022-08-01)

Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic
by: Renata Aiglova, et al.
Published: (2022-09-01)

Sacubitril/valsartan attenuates atrial conduction disturbance and electrophysiological heterogeneity with ameliorating fibrosis in mice
by: Satoshi Iwamiya, et al.
Published: (2024-01-01)

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF
by: Valeria Visco, et al.
Published: (2022-10-01)